» Articles » PMID: 25305096

Fatty Acid Synthase-associated Protein with Death Domain: a Prognostic Factor for Survival in Patients with Nasopharyngeal Carcinoma

Overview
Journal Hum Pathol
Specialty Pathology
Date 2014 Oct 12
PMID 25305096
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Fatty acid synthase-associated protein with death domain (FADD) is a key adaptor protein that bridges a death receptor (eg, death receptor 5) to caspase 8 to form the death-inducing signaling complex during apoptosis. The expression and prognostic impact of FADD in nasopharyngeal carcinoma (NPC) have not been well studied. This study focused on detecting FADD expression and analyzing its prognostic impact on NPC. FADD expression was assessed on pretreatment tumor tissues of 248 cases of NPC patients and 76 cases of noncancerous nasopharyngeal control tissue. The results showed that the positive percentage of FADD expression in NPC (63.7%, 158/248) was significantly higher than that in the noncancerous nasopharyngeal control tissues (28.9%, 22/76) (P < .0001). The positive expression of FADD in the NPC with cervical lymph node metastasis was significantly higher than those without lymph node metastasis (P = .009). Furthermore, FADD expression was more pronouncedly increased in metastatic NPC than the matched primary NPC tissues (P = .017). Both univariate and multivariate survival analysis indicated that increased FADD expression was significantly correlated inversely with overall survival in NPC patients (P = .003 and P = .007, respectively). Taken together, high expression of FADD may be an independent biomarker for poor prognosis in NPC.

Citing Articles

Yin Yang 1 suppresses tumor invasion and metastasis in nasopharyngeal carcinoma by negatively regulating eIF4E transcriptional activity and expression.

Li M, Duan Y, Wei J, Chen S, Xue C, Zheng L Am J Cancer Res. 2023; 13(8):3763-3780.

PMID: 37693135 PMC: 10492101.


YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.

Zhan Y, Chen X, Zheng H, Luo J, Yang Y, Ning Y Sci Rep. 2022; 12(1):3699.

PMID: 35260638 PMC: 8904596. DOI: 10.1038/s41598-022-07636-z.


Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma.

Huang H, Li S, Tang Q, Zhu G Front Immunol. 2021; 12:680955.

PMID: 34566954 PMC: 8458828. DOI: 10.3389/fimmu.2021.680955.


Co-expression of PD-L1 and HIF-1α predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.

Zheng H, Ning Y, Zhan Y, Liu S, Yang Y, Wen Q J Cancer. 2021; 12(7):2065-2072.

PMID: 33754005 PMC: 7974520. DOI: 10.7150/jca.53119.


Expression of DR5 and c‑FLIP proteins as novel prognostic biomarkers for non‑small cell lung cancer patients treated with surgical resection and chemotherapy.

Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Wen Q Oncol Rep. 2019; 42(6):2363-2370.

PMID: 31638235 PMC: 6859453. DOI: 10.3892/or.2019.7355.